In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa

被引：12
作者：
Piccoli, L
Guerrini, M
Felici, A
Marchetti, F
机构：
[1] GlaxoSmithKline SpA, Dept Med, I-37135 Verona, Italy
[2] GlaxoSmithKline SpA, Med Res Ctr, I-37135 Verona, Italy
来源：
JOURNAL OF CHEMOTHERAPY | 2005年 / 17卷 / 04期
关键词：
experimental infections; checkerboard testing; levofloxacin; ceftazidime; amikacin; Pseudomonas aeruginosa;
D O I：
10.1179/joc.2005.17.4.355
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The aim of the present study was to explore the antibacterial activity of the levofloxacin (LVX) and ceftazidime (CAZ) combination compared with the amikacin (AMK)/CAZ combination against Pseudomonas aeruginosa. Minimum inhibitory concentrations (MICs) were determined according to NCCLS. FIC indices (FI) were calculated by the checkerboard technique. CAZ combined with LVX or AMK yielded FIs indicating synergism (FI < 0.5) for 71/102 (69.6%) and 81/102 (79.4%)(p=0.108), indifference (FI > 0.5-4) for 24/102 (23.5%) and 12/102 (11.7%) (p=0.027), and antagonism (FI > 4) for 7/102 (6.8%) and 9/102 (8.8%) (p=0.602) strains, respectively. In vivo, CAZ/LVX was as bactericidal as CAZ/AMK combination. Our results support the potential role of LVX as an alternative to AMK in the combination therapy with CAZ in the treatment of P. aeruginosa severe infections. Anyway, further investigations and clinical trials are awaited until any definitive conclusions can be drawn.
引用
收藏
页码：355 / 360
页数：6
相关论文
共 31 条
[21]  
*MED LETT INC, 1999, MED LETT DRUGS THER, V41, P98
[22]  
National Committee for Clinical Laboratory Standards, 1997, METH DIL ANT SUSC TE
[23]   SYNERGY AND ANTAGONISM OF COMBINATIONS WITH QUINOLONES [J].
NEU, HC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (04) :255-261
[24]   Prevalence of nosocomial infections in 15 Italian hospitals: First point prevalance study for the INF-NOS project [J].
Nicastri, E ;
Petrosillo, N ;
Martini, L ;
Larosa, M ;
Gesu, GR ;
Ippolito, G .
INFECTION, 2003, 31 :10-15
[25]  
OREILLY T, 1996, ANTIBIOTICS LAB MED, P604
[26]   In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa [J].
Pendland, SL ;
Messick, CR ;
Jung, R .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 42 (01) :75-78
[27]  
PICCOLI L, 2000, 3 ESCMID INT S NOS I
[28]   Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa [J].
Segatore, B ;
Setacci, D ;
Perilli, M ;
Franceschini, N ;
De Santis, A ;
Marchetti, F ;
Amicosante, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :428-431
[29]   Application of different genotyping methods for Pseudomonas aeruginosa in a setting of endemicity in an intensive care unit [J].
Speijer, H ;
Savelkoul, PHM ;
Bonten, MJ ;
Stobberingh, EE ;
Tjhie, JHT .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (11) :3654-3661
[30]   Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology [J].
Visalli, MA ;
Jacobs, MR ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) :953-955
1234